GlassScriptPhysician profile
Kevin B Knopf
NPI 1881626687
$23,458.11
in general payments reported to CMS, 2019-2025
29 companies · $4,636 in 2025
The $4,636 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.78 · 2020: $7,921 · 2021: $9,857 · 2022: $450 · 2023: $26.14 · 2024: $525 · 2025: $4,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,688 · Food and Beverage: $1,277 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,687.50 |
| Food and Beverage | $1,277.05 |
| Education | $222.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $7,087.67 | 2020-2025 | Ninlaro, Fruzaqla, Iclusig |
| Eisai INC. | $3,184.00 | 2020 | |
| Seagen INC. | $2,816.74 | 2020-2025 | |
| Acceleron Pharma, INC. | $2,125.00 | 2021 | |
| Clinigen, INC. | $1,900.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,817.63 | 2021-2025 | Opdivo |
| Janssen Biotech, INC. | $1,374.39 | 2025 | Erleada, Carvykti, Rybrevant |
| Pfizer INC. | $910.66 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $525.00 | 2024 | Lynparza |
| Catalyst Pharmaceuticals, INC. | $500.00 | 2021 | |
| Alexion Pharmaceuticals, INC. | $250.00 | 2022 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Athenex Pharmaceutical Division, LLC | $175.00 | 2020 | |
| Glaxosmithkline, LLC. | $142.78 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.79 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $46.77 | 2025 | Yescarta |
| Merck Sharp & Dohme LLC | $46.01 | 2025 | Keytruda, Welireg |
| Daiichi Sankyo INC. | $43.97 | 2025 | Enhertu, Datroway |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.79 | 2025 | |
| Novartis Pharmaceuticals Corporation | $24.99 | 2025 | |
| Genmab U.S., INC. | $24.83 | 2025 | Epkinly |
| Apellis Pharmaceuticals, INC. | $22.83 | 2025 | Empaveli |
| Amgen INC. | $22.79 | 2025 | Lumakras, Imdelltra (Amg757) |
| Legend Biotech USA INC. | $21.47 | 2025 | Carvykti |
| Celgene Corporation | $20.98 | 2025 | Breyanzi |
| Array Biopharma INC | $20.53 | 2025 | Xalkori |
| Incyte Corporation | $18.74 | 2025 | Niktimvo, Jakafi |
| Rigel Pharmaceuticals, INC. | $16.51 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Azurity Pharmaceuticals, INC. | $16.24 | 2025 | Danziten |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Knopf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.